EUVIMEDEUVIMED entdecken
Open Access

Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome

Sachi Singhal iD, Emma D Riggs, Karen J Ruth, Juan Pablo Chavez-Salas iD, Yana Chertock, Mary B Daly, Michael J Hall iD

JCO Precision Oncology · 2024

DOI: 10.1200/po-24-00562 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Sachi Singhal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Genetics, Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, PA. Hauptthemen laut MEDLINE: Aspirin, Colorectal Neoplasms, Hereditary Nonpolyposis, Anti-Inflammatory Agents, Non-Steroidal, Chemoprevention. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Individuals with Lynch syndrome (LS) are at a high lifetime risk of colorectal cancer (CRC) and other cancers. Aspirin (ASA), a nonsteroidal anti-inflammatory drug (NSAID), has proven chemopreventive benefits in LS, with the CAPP2 randomized double-blind placebo-controlled trial demonstrating a 60% relative risk reduction for CRC among participants who adhered to ASA for 2 years or more. This study sought to characterize uptake of ASA/NSAIDs among individuals with LS and to understand factors associated with use. METHODS Individuals with LS were invited (June 2020-August 2022) to complete a one-time electronic survey about LS screening behaviors, uptake of ASA/NSAIDs, and current/emerging cancer prevention options. Participants were recruited from the Fox Chase Cancer Center (FCCC) Risk Assessment Program Registry and through a research invitation posted to two patient-facing LS advocacy websites. RESULTS Two hundred and ninety-six participants completed the survey including 116 (39.2%) from FCCC and 180 (60.8%) recruited via the Internet, including 14.9% non-US based individuals. Uptake of regular ASA or NSAIDs was modest at 34.8% and was even lower (25.7%) when focusing on individuals taking ASA or NSAIDs solely for chemoprevention of LS. More than half (55%) were taking

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinColorectal Neoplasms, Hereditary NonpolyposisAnti-Inflammatory Agents, Non-SteroidalChemopreventionHumansMaleFemaleMiddle AgedAdultAged

Substanzen

AspirinAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Department of Clinical Genetics, Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, PA.
  • Bioinformatics and Biostatistics, Fox Chase Cancer Center, Philadelphia, PA.

ORCID-Profile: Sachi Singhal, Juan Pablo Chavez-Salas, Michael J Hall

Förderung

  • NCI NIH HHS

Zitieren

APA

Singhal, S., Riggs, E. D., Ruth, K. J., Chavez-Salas, J. P., Chertock, Y., Daly, M. B., & Hall, M. J. (2024). Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome. JCO Precision Oncology. https://doi.org/10.1200/po-24-00562

Vancouver

Singhal S, Riggs ED, Ruth KJ, Chavez-Salas JP, Chertock Y, Daly MB, et al. Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome. JCO Precision Oncology. 2024. doi:10.1200/po-24-00562

BibTeX
@article{Singhal2024,
  author = {Singhal, Sachi and Riggs, Emma D and Ruth, Karen J and Chavez-Salas, Juan Pablo and Chertock, Yana and Daly, Mary B and Hall, Michael J},
  title = {Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome},
  journal = {JCO Precision Oncology},
  year = {2024},
  doi = {10.1200/po-24-00562}
}
Kostenlos starten →